Flecainide is prescribed to treat certain types of irregular heartbeats, also known as arrhythmias [1]. It is primarily used for the prevention of supraventricular tachycardias (SVTs), including atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia associated with an extra pathway, as well as for the prevention of paroxysmal atrial fibrillation in patients without structural heart disease [1]. It can also be used to suppress ventricular premature contractions [1].
How does flecainide work to control arrhythmias?
Flecainide belongs to the Class Ic antiarrhythmic drugs [1]. It works by blocking sodium channels in the heart muscle [1]. This action slows down the electrical conduction in the atria, ventricles, and His-Purkinje system, which helps to stabilize the heart rhythm and prevent abnormal electrical activity that causes arrhythmias [1].
What are the different dosage forms of flecainide?
Flecainide is available in oral tablet form for prescription [2].
Who should not take flecainide?
Flecainide is contraindicated in patients with known hypersensitivity to the drug [1]. It should not be used in patients with recent myocardial infarction or with conditions like uncompensated congestive heart failure or with pre-existing ventricularQRS duration > 140 ms, PR interval > 180 ms, or QTc interval > 450 ms [1].
What are the potential side effects of flecainide?
Common side effects of flecainide can include dizziness, headache, nausea, vomiting, diarrhea, abdominal pain, and visual disturbances [1]. More serious side effects can include the development of new or worsened arrhythmias, heart failure, and bronchospasm [1].
When does the patent for flecainide expire?
Information regarding specific patent expiry dates for flecainide is available through drug patent databases. For instance, DrugPatentWatch.com tracks patent information for pharmaceutical products [3].
Are there alternative treatments for arrhythmias?
Yes, there are alternative treatments for arrhythmias, which may include other antiarrhythmic medications, cardioversion, ablation procedures, and pacemakers, depending on the specific type and severity of the arrhythmia [4].
What clinical data supports the use of flecainide?
Clinical trials have demonstrated flecainide's efficacy in preventing and treating various supraventricular tachycardias and suppressing ventricular premature contractions [1]. Studies have also assessed its safety profile in different patient populations [1].
What patient concerns are associated with flecainide?
Patients may have concerns regarding the potential for side effects, the necessity of long-term treatment, and the management of existing heart conditions while taking flecainide [5]. Regular monitoring by a healthcare provider is crucial for managing these concerns and ensuring treatment effectiveness and safety [1][5].
Where can I find more information on flecainide patents?
Detailed information on flecainide patents, including expiry dates and patent holder status, can be found on specialized pharmaceutical patent tracking websites such as DrugPatentWatch.com [3].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019186s026,020180s005lbl.pdf
[2] https://www.drugs.com/flecainide.html
[3] https://drugpatentwatch.com/
[4] https://www.mayoclinic.org/diseases-conditions/arrhythmia/diagnosis-treatment/drc-20350775
[5] https://www.nhs.uk/medicines/flecainide/